MX2022008392A - Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. - Google Patents

Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.

Info

Publication number
MX2022008392A
MX2022008392A MX2022008392A MX2022008392A MX2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A MX 2022008392 A MX2022008392 A MX 2022008392A
Authority
MX
Mexico
Prior art keywords
methyl
phenylcyclohexyl
piperidine
oxy
carboxylate
Prior art date
Application number
MX2022008392A
Other languages
English (en)
Spanish (es)
Inventor
Hong Lu
Helene Faessel
Mark Rogge
Karthik Venkatakrishnan
Liming Zhang
John Wagner
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022008392A publication Critical patent/MX2022008392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022008392A 2020-01-10 2021-01-07 Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. MX2022008392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062959514P 2020-01-10 2020-01-10
PCT/US2021/012447 WO2021142083A1 (en) 2020-01-10 2021-01-07 A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450

Publications (1)

Publication Number Publication Date
MX2022008392A true MX2022008392A (es) 2022-08-08

Family

ID=74418549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008392A MX2022008392A (es) 2020-01-10 2021-01-07 Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.

Country Status (10)

Country Link
US (1) US12594269B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087534A1 (cg-RX-API-DMAC7.html)
JP (1) JP7728264B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220127245A (cg-RX-API-DMAC7.html)
CN (1) CN115226390B (cg-RX-API-DMAC7.html)
AU (1) AU2021205892B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022013547A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167050A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022008392A (cg-RX-API-DMAC7.html)
WO (1) WO2021142083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
EP4600242A1 (en) 2022-10-07 2025-08-13 Kissei Pharmaceutical Co., Ltd. Cyclopentane compound
KR20250085056A (ko) 2023-12-05 2025-06-12 안희태 국궁 과녁에서 영역 구분 센서의 구성 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
AU2014244518A1 (en) 2013-03-14 2015-09-17 Pharmacyclics Llc Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
MA45848A (fr) 2016-08-04 2019-06-12 Gilead Sciences Inc Cobicistat destiné à être utilisé dans des traitements du cancer
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用
WO2021048822A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Also Published As

Publication number Publication date
KR20220127245A (ko) 2022-09-19
AU2021205892A1 (en) 2022-08-18
WO2021142083A1 (en) 2021-07-15
BR112022013547A2 (pt) 2022-09-06
AU2021205892B2 (en) 2026-04-23
CN115226390B (zh) 2026-03-20
CA3167050A1 (en) 2021-07-15
EP4087534A1 (en) 2022-11-16
JP2023510332A (ja) 2023-03-13
CN115226390A (zh) 2022-10-21
JP7728264B2 (ja) 2025-08-22
US20230029486A1 (en) 2023-02-02
US12594269B2 (en) 2026-04-07

Similar Documents

Publication Publication Date Title
CA3174139A1 (en) Rna-editing compositions and methods of use
EP4628167A3 (en) Substituted macrocyclic compounds and related methods of treatment
EP4015654A4 (en) COMPOSITION, KIT AND METHOD FOR CORONAVIRUS DETECTION AND TYPING
EP4306116A3 (en) Methods and compositions for editing rnas
PH12021552613A1 (en) METHODS AND COMPOSITIONS FOR EDITING RNAs
BR112022003970A2 (pt) Métodos e composições para integração genômica
PH12022553269A1 (en) Composition, kit and method for detecting sars-cov-2 and use thereof
WO2021048821A8 (en) Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
MX2022012942A (es) Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina.
TN2009000249A1 (en) Mapk/erk kinase inhibitors
WO2008027932A3 (en) Cytochrome p450 oxidase inhibitors and uses thereof
BR112022013547A2 (pt) Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição
ZA202402178B (en) 3clpro protease inhibitor
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
TW200834248A (en) Liquid-immersion exposure method and liquid-immersion exposure apparatus
MX2022001933A (es) Inhibidores de enzimas.
MX2026002406A (es) Degradadores del transductor de señales y activador de la transcripción 6 (stat6) y usos de los mismos
CO2019001046A2 (es) Mancha blanca
TWI347627B (en) Work piece transfer appratus and method for an ion beam implanter
WO2022079128A3 (en) Compositions and methods for masking off-notes in consumables
TW200610036A (en) Improved magnet for scanning ion beams
SG126050A1 (en) Laser beam processing machine
MX2022016546A (es) Agente anticoccidio y metodo para su uso.
HRP20050557A2 (en) Method for improving the pharmacokinetics of a nnrti